We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
PhaseBio Pharmaceuticals has secured approval from the US Food and Drug Administration (FDA) to begin a VANGARD pivotal clinical to assess PB1046 as a treatment for hospitalised Covid-19 patients.